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ABSTRACT: 
The UDP-glucose pyrophosphorylase (GalU) of  Streptococcus pneumoniae is absolutely 
required for the biosynthesis of capsular polysaccharide, the sine qua non virulence factor of 
pneumococcus. Although GalU is widely distributed, the eukaryotic enzymes are completely 
unrelated to their prokaryotic counterparts; therefore, we proposed that pneumococcal GalU is 
an important target to expand our knowledge of the mechanisms underlying capsule formation. 
This could contribute to the development of new therapeutic strategies to fight the pneumococcus. 
A recombinant form of the pneumococcal GalU was purified from Escherichia coli and found to 
be stable and catalytically active. An average of 0.6 g of active rGalU was obtained from 100 ml 
of culture. We describe a GalU assay that is rapid, sensitive, and easy to perform in 96-well plates. 
The purified enzyme was tested in the presence of several drugs with structural similarity to natural 
substrates of the GalU enzyme. Our results document that this colorimetric test is appropriate 
for screening of chemical libraries for UDP-glucose pyrophosphorylase inhibitors. This work 
represents a fundamental step in the search of novel antipneumococcal drugs.










The worldwide increasing resistance of  bac-
terial pathogens to most of  the currently 
available antibiotics fosters the research for 
novel therapeutic drugs. The galU gene of 
Streptococcus pneumoniae encodes a UDP-glucose 
pyrophosphorylase (UDPG:PP) absolutely 
required for capsule biosynthesis. Although this 
gene is highly polymorphic, there is striking 
sequence conservation among the UDPG:PP of 
both Gram-positive and Gram-negative bacteria 
[1]. Also, a relevant role for GalU in virulence 
has been recognized in other bacteria since it is 
required for the synthesis of  UDPG, the main 
glucosyl donor in lipopolysaccharide and capsule 
biosynthesis [2–4]. Eukaryotic UDPG:PPs 
are completely unrelated to their bacterial 
counterparts, suggesting the possibility that 
inhibitors of the bacterial enzymes would not be 
harmful for the host. 
Previously, the galU gene was cloned, and 
overexpressed, and GalU was biochemically 
characterized [5, 6] and the galU expression was 
study [7].
We describe here the expression and purification 
in large scale of the pneumococcal GalU enzyme. 
Also, we propose a method to assay GalU activity 
with high sensitivity and in small volumes. This 
method would be useful for screening of potential 
GalU inhibitors of the enzyme that could behave 
as antipneumococcal drugs.
2. Materials and methods
The galU gene was cloned into pET28a to express 
a His6GalU fusion protein. His6GalU was purified 
using a NTA-Ni column.
A modification of colorimetric assay of ADPG:PP 
pyrophosphorylase was used [8].
3. Results and discussion
The recombinant GalU was overproduced in E. 
coli and purified (spec. act. 0.3 U/mg of protein). 
The pure enzyme was maintained stable at –20°C 
in 20% glycerol for at least 6 months. Several drugs 
with structural similarity to natural substrates of 
GalU were screening. We showed that after 30 min 
of pre-incubation with the putative inhibitor (7.5 
mM), there was an activity decrease of ca. 50%.
4. Conclusions
We document the successful preparation of 
rGalU from S. pneumoniae and the optimiza-
tion of  a colorimetric test appropriate for the 
screening of  UDPG:PP inhibitors. This work 
represents a fundamental step in the search of 
novel antipneumococcal drugs.
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